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Aromatase inhibitors versus tamoxifen in early breast 
cancer: patient-level meta-analysis of the randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Summary
Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast 
cancer remains uncertain.
Methods We undertook meta-analyses of individual data on 31 920 postmenopausal women with oestrogen-receptor-
positive early breast cancer in the randomised trials of 5 years of aromatase inhibitor versus 5 years of tamoxifen; of 
5 years of aromatase inhibitor versus 2–3 years of tamoxifen then aromatase inhibitor to year 5; and of 2–3 years 
of tamoxifen then aromatase inhibitor to year 5 versus 5 years of tamoxifen. Primary outcomes were any recurrence 
of breast cancer, breast cancer mortality, death without recurrence, and all-cause mortality. Intention-to-treat 
log-rank analyses, stratiﬁ ed by age, nodal status, and trial, yielded aromatase inhibitor versus tamoxifen ﬁ rst-event 
rate ratios (RRs).
Findings In the comparison of 5 years of aromatase inhibitor versus 5 years of tamoxifen, recurrence RRs favoured 
aromatase inhibitors signiﬁ cantly during years 0–1 (RR 0·64, 95% CI 0·52–0·78) and 2–4 (RR 0·80, 0·68–0·93), and 
non-signiﬁ cantly thereafter. 10-year breast cancer mortality was lower with aromatase inhibitors than tamoxifen 
(12·1% vs 14·2%; RR 0·85, 0·75–0·96; 2p=0·009). In the comparison of 5 years of aromatase inhibitor versus 
2–3 years of tamoxifen then aromatase inhibitor to year 5, recurrence RRs favoured aromatase inhibitors signiﬁ cantly 
during years 0–1 (RR 0·74, 0·62–0·89) but not while both groups received aromatase inhibitors during years 2–4, or 
thereafter; overall in these trials, there were fewer recurrences with 5 years of aromatase inhibitors than with 
tamoxifen then aromatase inhibitors (RR 0·90, 0·81–0·99; 2p=0·045), though the breast cancer mortality reduction 
was not signiﬁ cant (RR 0·89, 0·78–1·03; 2p=0·11). In the comparison of 2–3 years of tamoxifen then aromatase 
inhibitor to year 5 versus 5 years of tamoxifen, recurrence RRs favoured aromatase inhibitors signiﬁ cantly during 
years 2–4 (RR 0·56, 0·46–0·67) but not subsequently, and 10-year breast cancer mortality was lower with switching to 
aromatase inhibitors than with remaining on tamoxifen (8·7% vs 10·1%; 2p=0·015). Aggregating all three types of 
comparison, recurrence RRs favoured aromatase inhibitors during periods when treatments diﬀ ered (RR 0·70, 
0·64–0·77), but not signiﬁ cantly thereafter (RR 0·93, 0·86–1·01; 2p=0·08). Breast cancer mortality was reduced both 
while treatments diﬀ ered (RR 0·79, 0·67–0·92), and subsequently (RR 0·89, 0·81–0·99), and for all periods combined 
(RR 0·86, 0·80–0·94; 2p=0·0005). All-cause mortality was also reduced (RR 0·88, 0·82–0·94; 2p=0·0003). RRs 
diﬀ ered little by age, body-mass index, stage, grade, progesterone receptor status, or HER2 status. There were fewer 
endometrial cancers with aromatase inhibitors than tamoxifen (10-year incidence 0·4% vs 1·2%; RR 0·33, 0·21–0·51) 
but more bone fractures (5-year risk 8·2% vs 5·5%; RR 1·42, 1·28–1·57); non-breast-cancer mortality was similar. 
Interpretation Aromatase inhibitors reduce recurrence rates by about 30% (proportionately) compared with tamoxifen 
while treatments diﬀ er, but not thereafter. 5 years of an aromatase inhibitor reduces 10-year breast cancer mortality 
rates by about 15% compared with 5 years of tamoxifen, hence by about 40% (proportionately) compared with no 
endocrine treatment.
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Introduction
Treatment for 5 years with the selective oestrogen receptor 
(ER) modulator tamoxifen reduces recurrence rates in 
ER-positive early breast cancer by about half during 
treatment and about one-third in the subsequent 5 years, 
and reduces breast cancer mortality by almost one-third 
throughout the ﬁ rst 15 years.1 Further reductions in breast 
cancer mortality during years 10–14 are achieved by 
extending tamoxifen treatment to 10 years.2,3 In 
postmenopausal women only, aromatase inhibitors can 
greatly reduce oestrogen concentrations, hence avoiding 
stimulation of ER-positive breast cancer cells. Aromatase 
inhibitors, given either for 5 years or for 2–3 years after 
2–3 years of tamoxifen, produce greater reductions in 
recurrence than 5 years of tamoxifen alone,4 but the eﬀ ect 
on breast cancer mortality, and the optimal way to 
schedule aromatase inhibitors and tamoxifen in the 
treatment of early breast cancer, remain uncertain. 
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American Society of Clinical Oncology (ASCO) clinical 
practice guidelines reﬂ ect this, recom mending that 
postmenopausal women with early ER-positive breast 
cancer be oﬀ ered either tamoxifen for 10 years, an 
aromatase inhibitor for 5 years, tamoxifen initially for 
5 years followed by an aromatase inhibitor for up to a 
further 5 years, or tamoxifen for 2–3 years followed by an 
aromatase inhibitor for up to a further 5 years.5 To help 
clarify the relative beneﬁ ts of aromatase inhibitors and 
tamoxifen and the eﬀ ect of diﬀ erent scheduling during 
5 years of endocrine therapy, we undertook collaborative 
meta-analyses of individual patient data from the trials of 
aromatase inhibitors versus tamoxifen.
Methods
Identiﬁ cation of studies and collection of data
Trial identiﬁ cation, data checking, analysis, and 
involvement of trialists are as described in previous Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) 
reports.1,6,7 Eligible trials began by 2005 and randomised 
postmenopausal women with ER-positive early breast 
cancer between 5 years of an aromatase inhibitor versus 
5 years of tamoxifen (comparison A); 5 years of aromatase 
inhibitor versus 2–3 years of tamoxifen, then aromatase 
inhibitor to year 5 (comparison B); 2–3 years of tamoxifen, 
then aromatase inhibitor to year 5 versus 5 years of 
tamoxifen (comparison C); 5 years of aromatase inhibitor 
versus 2 years of aromatase inhibitor, then tamoxifen to 
year 5 (comparison D); or 2 years of aromatase inhibitor, 
then tamoxifen to year 5 versus 5 years of tamoxifen 
(comparison E). Separate analyses are provided for each 
of these comparisons (A–E), then results from some of 
them are combined.
Information was sought during 2012–14 for each 
individual patient on randomisation date, allocated 
treatment, age, menopausal status, body-mass index 
(BMI), tumour diameter, grade, spread to locoregional 
lymph nodes, ER, progesterone receptor (PR), and HER2 
receptor status, and dates of any locoregional, 
contralateral, or distant breast cancer recurrence, other 
second primary cancer, bone fractures, death, and cause 
of death.
Outcomes
The primary outcomes were any recurrence of breast 
cancer (distant, locoregional, or new primary in the 
contralateral breast); breast cancer mortality; death 
without recurrence; and all-cause mortality. Secondary 
outcomes were incidence and site of second primary 
cancers, and bone fracture. Prespeciﬁ ed primary subgroup 
investigations were of site of recurrence, age, nodal status, 
PR status, histological grade, and follow-up period.
Statistical analyses
Statistical methods (stratiﬁ ed log-rank statistics, Kaplan-
Meier graphs) are described elsewhere.1,6,7 Time-to-event 
analyses were stratiﬁ ed by age, nodal status, and trial. 
Within each stratum, they compared all those allocated 
aromatase inhibitor versus all those allocated tamoxifen, 
regardless of treatment compliance (yielding intention-to-
treat analyses). Log-rank statistics were used to assess the 
eﬀ ects (aromatase inhibitor vs tamoxifen) on various 
outcomes, and, for each, to estimate ﬁ rst-event-rate ratios 
(RRs) and their CIs. If a log-rank statistic (o – e) has 
variance v, then, deﬁ ning z=(o – e)/√v and b=(o – e)/v, b has 
variance 1/v and the event RR (newer treatment vs control) 
is estimated as exp(b) with SE=(RR – 1)/z. CIs for RR are 
derived from those for b (by normal approximations). 2p 
indicates two-sided signiﬁ cance. The breast cancer 
mortality rate in each year is the overall mortality rate 
among all women minus that among women of similar 
age without recurrence. Breast cancer mortality RRs are 
estimated from the corresponding log-rank analyses of 
mortality with recurrence (obtained by subtracting 
log-rank analyses of mortality without recurrence [ie, 
censored at recurrence] from those of overall mortality). 
Analyses used EBCTCG Fortran programs. The policy on 
data sharing from this study is available online.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The secretariat had full access to all 
data and the writing committee had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Individual patient datasets were provided for nine trials,8–16 
including 35 129 (98%) of the 35 718 women randomised 
between aromatase inhibitor and tamoxifen as part of 
about 5 years of adjuvant endocrine treatment (appendix). 
This report is restricted to the 31 920 (91%) with ER-positive 
tumours of these 35 129 patients. All were randomised 
evenly between aromatase inhibitor and tamoxifen, though 
one trial (BIG 1-988) included a four-way randomisation 
that contributes data to all ﬁ ve comparisons (A–E); the 
aggregated analyses avoid double counting its results. 
When reports emerged that patients on tamoxifen had 
their recurrence risk reduced by switching after 2–3 years 
to an aromatase inhibitor, crossover to an aromatase 
inhibitor from the tamoxifen-only group was systematically 
oﬀ ered in two trials (BIG 1-98,8 25% [619/2459] crossover; 
ABCSG-8,9 18% [341/1949] crossover). In eight trials, 
compliance was similar in both groups, but in TEAM10 56% 
(2698/4814) of those allocated tamoxifen then aromatase 
inhibitor versus 30% (1438/4852) of those allocated only 
aromatase inhibitor discontinued treatment prematurely.
In comparison A (5 years of aromatase inhibitor vs 
5 years of tamoxifen: two trials, n=9885), recurrence and 
mortality were both signiﬁ cantly reduced (ﬁ gure 1). The 
numbers with recurrence were 827 in the aromatase 
inhibitor group versus 964 in the tamoxifen group 
(p<0·00001), with separately signiﬁ cant reductions 
during years 0–1 after surgery (RR 0·64, 95% CI 
For the CTSU policy on data 
sharing see http://www.ctsu.ox.
ac.uk/research/data-access-
policies/data-access-and-
sharing-policy/view
See Online for appendix
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0·52–0·78) and during years 2–4 (RR 0·80, 0·68–0·93), 
but no signiﬁ cant further eﬀ ect after the scheduled 
treatment period, and little follow-up beyond year 10. 
The 10-year recurrence risk was 19·1% in the aromatase 
inhibitor group versus 22·7% in the tamoxifen group 
(diﬀ erence 3·6%, 95% CI 1·7–5·4). Distant recurrence 
(RR 0·86, 95% CI 0·77–0·96; 2p=0·007), local recurrence 
(RR 0·74, 0·58–0·95; 2p=0·020), and contralateral 
recurrence (RR 0·62, 0·48–0·80; 2p=0·0003) were all 
reduced (appendix). Breast cancer mortality was also 
reduced (RR 0·85, 95% CI 0·75–0·96; 2p=0·009), as was 
all-cause mortality (936 vs 1000 deaths; RR 0·89, 
0·81–0·97; 2p=0·010), even though half the deaths were 
from non-breast cancer causes that are little aﬀ ected by 
treatment.
In comparison B (5 years of aromatase inhibitor vs 
2–3 years of tamoxifen then aromatase inhibitor to year 5: 
three trials, n=12 779), recurrence was signiﬁ cantly 
reduced only during years 0–1 (RR 0·74, 95% CI 
0·62–0·89; 2p=0·002), ie, when the treatments diﬀ ered, 
and was similar during years 2–4 (RR 0·99, 0·85–1·15), 
when both groups were receiving an aromatase inhibitor 
(ﬁ gure 2). There was no signiﬁ cant further eﬀ ect after 
year 5, but little follow-up beyond year 7. Perhaps because 
the period during which the treatments diﬀ ered lasted 
only half as long as in comparison A, the absolute 
reductions in recurrence and mortality appeared smaller. 
The total numbers with recurrence were 705 in the 
aromatase inhibitor group versus 765 in the tamoxifen 
group (2p=0·045). Although breast cancer mortality 
appeared somewhat reduced (RR 0·89, 95% CI 
0·78–1·03; 2p=0·11), this was not signiﬁ cant, and nor 
were the eﬀ ects on other mortality or all-cause mortality.
In comparison C (2–3 years of tamoxifen then aromatase 
inhibitor to year 5 vs 5 years of tamoxifen: six trials, 
n=11 798), recurrence and mortality were both signiﬁ cantly 
reduced (ﬁ gure 3). Four trials did not randomise until after 
2 years of tamoxifen, but two randomised at year 0; for 
comparability with the other four, only patients who 
completed 2 years of tamoxifen without recurrence or a 
second primary are included, but sensitivity analyses 
(appendix) show this exclusion made little diﬀ erence. 
Starting from when treatments diverged, the numbers 
with recurrence were 753 in the aromatase inhibitor group 
versus 863 in the tamoxifen group (2p=0·0001). Allocation 
to an aromatase inhibitor reduced the recurrence rate 
during years 2–4 (RR 0·56, 95% CI 0·46–0·67; p<0·0001), 
with no signiﬁ cant further eﬀ ect on recurrence after the 
treatment period, and little follow-up beyond year 10. The 
10-year recurrence risk was 17·0% in the aromatase 
inhibitor group versus 19·0% in the tamoxifen group 
(diﬀ erence 2·0, 95% CI 0·2–3·8). Distant recurrence 
(RR 0·86, 95% CI 0·77–0·97; 2p=0·02), and contralateral 
recurrence (RR 0·67, 0·51–0·87; 2p=0·002) were both 
reduced (appendix). Breast cancer mortality was also 
reduced (RR 0·84, 95% CI 0·72–0·96; 2p=0·015), as was 
all-cause mortality (639 vs 764 deaths; RR 0·82, 0·73–0·91; 
2p=0·0002), helped by what might have been a chance 
reduction in non-breast cancer mortality.
The recurrence results already described for 
comparisons A–C are summarised in the appendix, using 
black squares for periods when the treatments diﬀ ered 
(aromatase inhibitor in one group vs tamoxifen in the 
other) and open squares for periods when they did not. It 
also gives the comparisons D and E, which both derive 
from BIG 1-98.8 Comparison D was restricted to the 
2558 women who were recurrence free and still on 
treatment after 2 years of aromatase inhibitor. Although 
they suggest no apparent gain from continuing to take an 
aromatase inhibitor rather than switching to tamoxifen 
after 2 years, the CIs were wide. Comparison E included 
3060 women; the proportional recurrence reduction 
during years 0–1 (when the treatments diﬀ ered) was 
similar to that in earlier comparisons, and the apparent 
ﬂ uctuations in the recurrence RR during the period when 
the treatments no longer diﬀ ered could well be chance.
In each of comparisons A–C there was signiﬁ cant 
beneﬁ t only when treatments diﬀ ered and not when they 
were the same in both groups. This pattern is even 
clearer when results from all ﬁ ve comparisons are 
aggregated by time period (ﬁ gure 4). Recurrence RRs 
favoured aromatase inhibitors during periods when 
treatments diﬀ ered (RR 0·70, 95% CI 0·64–0·77), but not 
signiﬁ cantly thereafter (RR 0·93, 0·86–1·01; 2p=0·08). 
The recurrence rate was about 30% lower with an 
aromatase inhibitor than with tamoxifen in years 
0–1 (RR 0·70, 95% CI 0·61–0·80; 2p<0·0001), and in 
years 2–4 (RR 0·71, 0·62–0·80; 2p<0·0001). Combining 
trials where treatments diﬀ ered only during years 0–1 
and not during years 2–4, there was no reduction in 
recurrence during years 2–4 (RR 1·03, 95% CI 
0·87–1·22). There was little further eﬀ ect during years 
5–9 when no further treatment was scheduled (RR 0·92, 
95% CI 0·83–1·01), and little follow-up beyond year 10.
Breast cancer mortality was reduced both while 
treatments diﬀ ered (RR 0·79, 95% CI 0·67–0·92), and 
subsequently (RR 0·89, 0·81–0·99), and for all periods 
combined (RR 0·86, 0·80–0·94; p=0·0005; appendix). 
All-cause mortality was likewise reduced (RR 0·90, 95% 
CI 0·84–0·95; 2p=0·0005).
To enhance statistical power, the main subgroup analyses 
of recurrence are restricted to the periods when aromatase 
inhibitor was directly compared with tamoxifen (ﬁ gure 5). 
The ﬁ rst such analyses compare the six components 
from previous ﬁ gures that contribute to this: the recurrence 
RRs during years 0–1 were, as expected, similar in 
comparisons A, B, and E, but the recurrence RRs during 
years 2–4 appeared somewhat more extreme after 2–3 years 
of previous tamoxifen (RR 0·56, 95% CI 0·46–0·67) than 
after 2–3 years of aromatase inhibitor versus tamoxifen 
(RR 0·83, 0·69–1·00), or after 2 years of aromatase 
inhibitor (RR 1·08, 0·70–1·68).
Figure 5 subdivides the aggregated result from the 
periods when treatments diﬀ ered by aromatase 
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inhibitor drug, site of ﬁ rst recurrence, entry age, BMI, 
and tumour characteristics: PR status, nodal status, 
tumour diameter, tumour grade, and HER2 status 
(available for only one-third of patients). The recurrence 
RRs were similar with diﬀ erent aromatase inhibitors 
(each p<0·0001), with local recurrence, contralateral 
0 5 10
0
10
20
30
40
50
A
Re
cu
rre
nc
e 
(%
)
Recurrence rate/year (%), events/woman-years and log-rank statistics
Allocation
AI
Tamoxifen
Rate ratio (95% CI) 
from (O-E)/V
Years 0–1
1·62 (157/9691)
2·41 (230/9542)
0·64 (0·52–0·78)
–41·1/92·8
Years 2–4
2·14 (285/13 336)
2·62 (338/12 906)
0·80 (0·68–0·93)
–34·1/149·0
Years 5–9
2·33 (365/15 648)
2·48 (372/14 985)
0·92 (0·79−1·06)
−15·5/177·2
Year 10+
3·23 (20/619)
4·54 (24/529)
0·72 (0·39−1·30)
−3·6/10·7
9885 women, 1791 events
RR=0·80 (95% CI 0·73–0·88)
0 5 10
0
10
20
30
40
50
B
Br
ea
st
 ca
nc
er
 m
or
ta
lit
y 
(%
)
Death rates (%/year: total rate minus rate in women without recurrence) and log-rank statistics
Allocation
AI
Tamoxifen
Rate ratio (95% CI) 
from (O-E)/V
Years 0–1
0·52 (0·39−0·66)
0·51 (0·39−0·67)
0·98 (0·66−1·46)
−0·4/24·3
Years 2–4
1·23 (1·05−1·41)
1·60 (1·38−1·83)
0·74 (0·60−0·91)
−27·2/90·7
Years 5–9
1·66 (1·46−1·86)
1·81 (1·60−2·02)
0·90 (0·76−1·07)
−13·6/129·4
Year 10+
1·93 (0·88−2·99)
1·88 (0·77−2·99)
1·01 (0·45−2·33)
0·1/5·6
9885 women, 1066 deaths
RR=0·85 (95% CI 0·75–0·96)
0 5 10
Years
0
10
20
30
40
50
C
De
at
h 
w
ith
ou
t r
ec
ur
re
nc
e 
(%
)
Death-without-recurrence rate/year (%), events/woman-years and log-rank statistics
Allocation
AI
Tamoxifen
Rate ratio (95% CI) 
from (O-E)/V
Years 0–1
0·54 (52/9691)
0·60 (57/9542)
0·89 (0·61−1·30)
−3·2/27·0
Years 2–4
0·99 (132/13 336)
0·95 (122/12 906)
1·03 (0·81−1·32)
2·0/62·5
Years 5–9
1·46 (229/15 648)
1·63 (244/14 985)
0·88 (0·73−1·05)
−14·9/114·4
Year 10+
3·07 (19/619)
2·84 (15/529)
1·28 (0·64−2·56)
2·0/8·1
9885 women, 870 deaths
RR=0·94 (95% CI 0·82–1·07)
0 5 10
Years
0
10
20
30
40
50
D
De
at
h 
fro
m
 a
ny
 ca
us
e 
(%
)
Death rate/year (%), events/woman-years and log-rank statistics
Allocation
AI
Tamoxifen
Rate ratio (95% CI) 
from (O-E)/V
Years 0–1
1·05 (103/9775)
1·10 (106/9661)
0·93 (0·71−1·23)
−3·6/51·3
Years 2–4
2·18 (301/13 777)
2·50 (338/13 506)
0·85 (0·72−0·99)
−25·2/153·2
Years 5–9
3·06 (500/16 333)
3·35 (530/15 805)
0·89 (0·79−1·01)
−28·4/243·9
Year 10+
4·76 (32/672)
4·44 (26/586)
1·16 (0·69−1·99)
2·1/13·6
9885 women, 1936 deaths
RR=0·89 (95% CI 0·8–0·97)
10-year gain 3·6% (95% CI 1·7 to 5·4)
Log-rank 2p<0·00001
Tamoxifen
22·7%
AI
19·1%
12·1%
9·0%
10-year gain 2·1% (95% CI 0·5 to 3·7)
Log-rank 2p=0·009
Tamoxifen
14·2%
AI
12·1%
5·8%
4·5%
10-year gain 1·1% (95% CI –0·4 to 2·6)
Log-rank 2p=0·34
Tamoxifen
11·9%
AI
10·8%
4·0%
4·0%
10-year gain 2·7% (95% CI 0·1 to 4·7)
Log-rank 2p=0·01
Tamoxifen
24·0%
AI
21·3%
9·4%
8·2%
Figure 1: 5 years of aromatase inhibitor versus 5 years of tamoxifen
(A) Recurrence, (B) breast cancer mortality, (C) death without recurrence, and (D) death from any cause. RR=rate ratio (with 95% CI). AI=aromatase inhibitor. O–E=observed minus expected. V=variance 
of O–E.
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breast cancer, and distant recur rence all substantially 
reduced by aromatase inhibitor compared with 
tamoxifen. In the aggregated data, the RRs while 
treatments diﬀ ered appeared similar in every subgroup, 
suggesting that age, BMI, and tumour characteristics 
cannot usefully predict the RR.
Figure 2: 5 years of aromatase inhibitor versus tamoxifen to years 2–3 then aromatase inhibitor to year 5
(A) Recurrence, (B) breast cancer mortality, (C) death without recurrence, and (D) death from any cause. RR=rate ratio. AI=aromatase inhibitor. O–E=observed minus expected. V=variance of O–E.
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Tumour characteristics were, however, importantly 
predictive of the absolute risk of recurrence, and hence 
of the absolute eﬀ ect on breast cancer outcomes of 
giving an aromatase inhibitor rather than tamoxifen 
(appendix). For example, in the aggregate of the trials 
that contribute to the black squares in ﬁ gure 4, the 
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0·73 (0·60–0·89)
−30·3/95·3
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Death rate/year (%), events/woman-years and log-rank statistics
Allocation
Tamoxifen then AI
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Rate ratio (95% CI)
from (O-E)/V
Years 2–4
0·88 (102/11 644)
1·10 (128/11 618)
0·78 (0·60–1·01)
−13·9/55·9
Years 5–9
2·09 (437/20 949)
2·47 (509/20 593)
0·83 (0·73–0·95)
−42·3/227·3
Year 10+
1·86 (50/2696)
2·11 (53/2505)
0·95 (0·63–1·42)
−1·3/23·8
11 798 women, 1403 deaths
RR=0·82 (95% CI 0·73–0·91)
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Figure 3: Tamoxifen to years 2–3 then aromatase inhibitor to year 5 versus 5 years of tamoxifen: events in women alive and free of recurrence when treatments diverged
(A) Recurrence, (B) breast cancer mortality, (C) death without recurrence, and (D) death from any cause. RR=rate ratio. AI=aromatase inhibitor. O–E=observed minus expected. V=variance of O–E.
Articles
www.thelancet.com   Vol 386   October 3, 2015 1347
overall Kaplan-Meier estimate of the 5-year recurrence 
risk was reduced by 2·5% (7·3% vs 9·8%, appendix). 
But, in this same data set, the 5-year recurrence risks for 
women with N0, N1–3, and N4+ disease were reduced by 
1·2%, 3·7%, and 6·4%, respectively.
Similar sets of subgroup analyses for each separate 
category of comparisons A–E are in the appendix, but 
with so many subgroup analyses the apparent ﬁ ndings 
should be interpreted cautiously, as striking false-positive 
and false-negative results can easily arise just by chance. 
For example, the hypothesis from ATAC15 of a more 
extreme recurrence RR in ER-positive PR-negative than 
in ER-positive PR-positive disease is not supported by 
evidence from other trials (ﬁ gure 5, appendix). Likewise, 
the hypothesis from comparison C of equivalent eﬃ  cacy 
of aromatase inhibitors and tamoxifen in node-negative 
disease is not supported by evidence from the other 
comparisons. Such patterns might be due mainly 
to chance.
Results for cause-speciﬁ c mortality, second cancer 
incidence, and bone fracture before any breast cancer 
recurrence are in the appendix. There was a signiﬁ cant 
reduction in mortality without recurrence in 
comparison C (tamoxifen then aromatase inhibitor vs 
tamoxifen alone) that was not explained by any 
particular cause and is unlikely to be due to 
misclassiﬁ ed breast cancer deaths (partly because the 
non-breast-cancer mortality rates were sharply age-
related whereas breast cancer mortality rates were 
similar in all age groups).
There were fewer uterine cancers and more bone 
fractures with aromatase inhibitors than with tamoxifen. 
Aggregating the ﬁ ve comparisons, the 10-year incidence 
of endometrial cancer (deﬁ ned as any uterine cancer 
except cervix cancer) was 0·4% in the aromatase inhibitor 
group versus 1·2% in the tamoxifen group (absolute 
diﬀ erence 0·8%, 95% CI 0·6–1·0; p<0·0001), including 
ﬁ ve versus nine deaths. The proportional decrease in 
endometrial cancer incidence with aromatase inhibitors 
(RR 0·33, 0·21–0·51) was approximately independent of 
age and persisted for some years after treatment ended. 
As endometrial cancer increases with age, the absolute 
excess with tamoxifen was 0·7% (95% CI 0·5–0·9) at 
ages 55–69 and 1·4% (95% CI 0·5–2·4) at older ages 
(appendix). There was no signiﬁ cant eﬀ ect on any other 
type of cancer (except for contralateral breast cancer).
The incidence of bone fractures was increased among 
aromatase-inhibitor-allocated patients during years 0–4 
(RR 1·42, 95% CI 1·28–1·57; p<0·0001), and remained 
signiﬁ cantly higher through years 5–9 (RR 1·29, 
1·09–1·53; 2p=0·003) despite fractures being monitored 
less reliably after the 5-year treatment period. The 5-year 
fracture risk was 8·2% in the aromatase inhibitor group 
versus 5·5% in the tamoxifen group (absolute excess 
2·7%, 95% CI 1·7–3·7). Again, the proportional increase 
appeared approximately independent of age and the 
absolute incidence increased with age. Hence, among 
women of age younger than 55, 55–69, and older than 
70 years at randomisation, the absolute excess risks 
(aromatase inhibitor vs tamoxifen) of having a fracture 
Figure 4: Recurrence reductions by time since surgery, combining data from diﬀ erent comparisons of aromatase inhibitor (AI) versus tamoxifen treatment as 
part of 5 years of endocrine therapy
Black squares show periods when the protocol speciﬁ ed that one group should receive an aromatase inhibitor and the other should receive tamoxifen; open squares 
show periods when the treatments should have been the same in both groups. *Aggregated totals are adjusted to avoid double counting of events in the four-way 
randomisation in BIG 1-98. AI=aromatase inhibitor. O–E=observed minus expected.
Events/women–years (%/year)
Allocated 
AI
Allocated 
tamoxifen
(a)  AI vs tamoxifen
 Years 0–1 AI vs tamoxifen
 Years 2–4 AI vs tamoxifen
                Subtotal  
 361/22 068 (1·6)
 425/23 324 (1·8)
 786/45 398 (1·7%/year)
 502/21 786 (2·3)
 581/22 803 (2·5)
 1083/44 589 (2·4%/year)
0·70 (0·58–0·84)
0·71 (0·60–0·83)
0·70 (0·64–0·77)
           2p<0·00001
 –74·3
 –83·7
 –158·1
 207·6
 240·2
 447·7
(b)  Same or no treatment
 Years 2–4 same treatment
 Years 5–9 no treatment
 Years 10+ no treatment
                   Subtotal
                       Total (a+b)
            99% or             95% CIs
Diﬀerence between treatment eﬀects in two subtotals χ21=21·1; 2p<0·00001
Heterogeneity within subtotals χ23=2·0; 2p=0·6  
Heterogeneity between ﬁve comparisons χ24=23·1; 2p=0·0001  
287/11 340 (2·5)
906/38 062 (2·4)
109/3384 (3·2)
1302/52 786 (2·5%/year)
2088/98 184 (2·1%/year)
266/10 954 (2·4)
940/36 499 (2·6)
114/3111 (3·7)
1320/50 564 (2·6%/year)
2403/95 153 (2·5%/year)
1·03 (0·83–1·29)
0·92 (0·81–1·03)
0·85 (0·60–1·21)
0·93 (0·86–1·01)
           2p=0·08
0·829 (0·781–0·880)
           2p<0·00001
 4·2
 –39·0
 –8·6
 –43·5
 –201·5
 133·1
 443·7
 53·1
 629·9
 1077·7
AI events Ratio of annual event rates
AI:tamoxifen
Rate ratio (CI)
Log-rank 
O–E
Variance 
of O–E
AI better Tamoxifen better
Treatment eﬀect 2p<0·00001
0 0·5 1·0 1·5 2·0
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AI better Tamoxifen better
Treatment eﬀect 2p<0·00001
0 0·5 1·0 1·5 2·0
Events/women-years (%/year)
Allocated 
AI
Allocated 
tamoxifen
(a) Treatment comparison (χ25=13·3; p=0·02)
Years 0–1 comparison
Years 0–1 comparison
Years 0–1 comparison
Years 2–4 comparison
Years 2–4 comparison
Years 2–4 comparison
(b) AI agent (χ22=0·5; 2p=0·8)
Anastrozole
Exemestane
Letrozole
(c) Site of recurrence (χ22=1·5; 2p=0·5)
Distant
Isolated local
Contralateral
(d) Age (trend χ21=2·2; 2p=0·14)
<45 years
45–54 years
55–69 years
70+ years
(e) BMI (trend χ21=0·3; 2p=0·6)
<20
20–24
25–29
30+
Unknown
(f) PR status (χ21=5·7; 2p=0·02)
ER positive PR negative
ER positive PR unknown
ER positive PR positive
(g) Nodal status (trend χ21=0·0; 2p=1·0)
N0/N–
N1–3
N4+
N other/unknown
(h) T stage (trend χ21=2·8; 2p=0·09)
1–20 mm (T1)
21–50 mm (T2)
>50 mm (T3/T4)
Other/unknown
(i) Tumour grade (trend χ21=0·0; 2p=1·0)
Well diﬀerentiated
Moderately
Poorly
Grade unknown
(j) HER2 status (χ22=0·0; 2p=1·0)
HER2 positive
HER2 negative
Unknown
           Total
        A 157/9676 (1·6)
        B 204/12 418 (1·6)
        E 35/2995 (1·2)
        A 285/13 313 (2·1)
        C 170/11 498 (1·5)
        D 43/2505 (1·7)
 291/16 842 (1·7)
 233/13 164 (1·8)
 262/15 392 (1·7)
  617/45 398 (1·4)
 101/45 398 (0·2)
 68/45 398 (0·1)
 4/215 (1·9)
 108/6636 (1·6)
 472/27 362 (1·7)
 202/11 185 (1·8)
 21/1506 (1·4)
 194/11 001 (1·8)
 202/11 397 (1·8)
 166/6814 (2·4)
 203/14 195 (1·4)
 171/6928 (2·5)
 49/2259 (2·2)
 566/36 243 (1·6)
 243/26 174 (0·9)
 280/13 746 (2·0)
 236/4067 (5·8)
 27/1411 (1·9)
 324/28 854 (1·1)
 401/14 714 (2·7)
 42/1116 (3·8)
 19/708 (2·7)
 60/8857 (0·7)
 320/21 782 (1·5)
 238/7557 (3·1)
 168/7193 (2·3)
 79/3264 (2·4)
 112/8854 (1·3)
 595/33 280 (1·8)
 786/45 398 (1·7%/year)
 230/9526 (2·4)
 273/12 273 (2·2)
 45/3008 (1·5)
 338/12 886 (2·6)
 300/11 333 (2·6)
 41/2491 (1·6)
 387/16 415 (2·4)
 341/12 990 (2·6)
 355/15 184 (2·3)
 819/44 590 (1·8)
 158/44 590 (0·4)
 106/44 590 (0·2)
 9/183 (4·9)
 144/6430 (2·2)
 616/27 152 (2·3)
 314/10 824 (2·9)
 26/1328 (2·0)
 272/10 695 (2·5)
 264/11 016 (2·4)
 203/7477 (2·7)
 318/14 073 (2·3)
 284/6687 (4·2)
 57/2385 (2·4)
 742/35 556 (2·1)
 338/26 097 (1·3)
 390/13 285 (2·9)
 308/3850 (8·0)
 47/1357 (3·5)
 409/28 134 (1·5)
 576/14 738 (3·9)
 74/1008 (7·3)
 24/710 (3·4)
 84/8839 (1·0)
 452/21 382 (2·1)
 318/7287 (4·4)
 229/7081 (3·2)
 108/3074 (3·5)
 166/8733 (1·9)
 809/32 782 (2·5)
 1083/44 589 (2·4%/year)
0·64 (0·49–0·84)
0·74 (0·59–0·95)
0·78 (0·43–1·40)
0·80 (0·64–0·98)
0·56 (0·44–0·71)
1·08 (0·61–1·92)
0·71 (0·58–0·87)
0·67 (0·54–0·84)
0·73 (0·59–0·91)
0·73 (0·63–0·84)
0·64 (0·46–0·88)
0·64 (0·43–0·94)
0·73 (0·52–1·01)
0·75 (0·64–0·88)
0·60 (0·48–0·76)
0·79 (0·36–1·74)
0·71 (0·55–0·90)
0·72 (0·56–0·92)
0·79 (0·60–1·04)
0·63 (0·51–0·79)
0·57 (0·45–0·73)
0·91 (0·55–1·51)
0·74 (0·64–0·86)
0·72 (0·58–0·89)
0·68 (0·56–0·84)
0·73 (0·58–0·92)
0·59 (0·32–1·09)
0·76 (0·63–0·92)
0·70 (0·59–0·82)
0·51 (0·30–0·85)
0·71 (0·46–1·09)
0·68 (0·57–0·83)
0·70 (0·56–0·87)
0·71 (0·54–0·92)
0·66 (0·45–0·99)
0·67 (0·49–0·92)
0·71 (0·62–0·82)
0·702 (0·640–0·771)
             2p<0·00001
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 −9·4
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 −17·5
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 111·5
 20·1
 163·2
 137·9
 149·6
 344·5
 64·3
 43·4
 1·4
 60·4
 262·2
 123·7
 10·7
 109·1
 111·1
 86·8
 133·7
 109·2
 25·8
 320·1
 143·4
 162·4
 124·4
 17·5
 179·2
 233·8
 25·3
 9·7
 35·1
 188·0
 131·3
 95·5
 43·0
 65·4
 339·3
 447·7
AI events Ratio of annual event rates
AI:tamoxifen
Rate ratio (CI)
Log-rank 
O–E
Variance 
of O–E
              99% or              95% CIs
  
Figure 5: Subgroup analyses 
of recurrence risk reductions 
combining data from 
ﬁ ve comparisons of 
aromatase inhibitors versus 
tamoxifen including only 
data during periods when 
treatments diﬀ ered
Grey squares show unknown 
status within the subgroup. 
Results are plotted as black 
squares with horizontal lines 
that denote 99% rather than 
95% CIs to allow for multiple 
hypothesis testing. Total is 
plotted as a white diamond 
that denotes 95% CI. 
AI=aromatase inhibitor. 
O–E=observed minus 
expected. 
Comparison A=5 years of 
aromatase inhibitor versus 
5 years of tamoxifen. 
Comparison B=5 years of 
aromatase inhibitors versus 
2–3 years of tamoxifen, then 
aromatase inhibitor to year 5. 
Comparison C=2–3 years of 
tamoxifen, then aromatase 
inhibitor to year 5 versus 
5 years of tamoxifen. 
Comparison D=5 years of 
aromatase inhibitor versus 
2 years of aromatase inhibitor, 
then tamoxifen to year 5. 
Comparison E=2 years of 
aromatase inhibitor, then 
tamoxifen to year 5 versus 
5 years of tamoxifen. 
ER=oestrogen receptor. 
PR=progesterone receptor.
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within 5 years were, respectively, about 1%, 2%, and 4% 
(appendix). Diﬀ erences in vascular mortality, aromatase 
inhibitor versus tamoxifen, were not signiﬁ cant: 
thromboembolic, 14 versus 19 deaths; cerebrovascular, 
44 versus 52 deaths; and cardiac, 137 versus 128 deaths.
Discussion
Individual trials have already shown reduced recurrence 
rates with aromatase inhibitor compared with tamoxifen 
but none has shown in intention-to-treat analyses that 
breast cancer mortality is reduced, nor did previous 
meta-analyses.4 Now, with longer follow-up, the present 
meta-analyses establish that breast cancer mortality and 
all-cause mortality are also reduced, better characterise 
time-dependent eﬀ ects on recurrence, and allow 
informative investigation of diﬀ erential eﬃ  cacy within 
subgroups and of uncommon adverse events.
There was a fairly consistent pattern of substantial 
recurrence reductions during periods when one group 
was receiving an aromatase inhibitor and the other 
tamoxifen, but little further reduction during subsequent 
periods when both groups were receiving the same 
endocrine treatment or after scheduled endocrine 
treatment had ended in both groups. However, this 
ﬁ nding should not be interpreted as aromatase inhibitors 
not having the carry-over beneﬁ ts of tamoxifen,1 rather 
that 5 years of endocrine therapy that includes an 
aromatase inhibitor reduces recurrence by about 
one-third during years 5–9, as does 5 years of tamoxifen.
The most extreme recurrence reduction appeared to be 
in comparison C in which, after 2 years of tamoxifen, an 
aromatase inhibitor was compared with tamoxifen during 
years 2–4. This result is not explained by diﬀ erences 
in eﬃ  cacy between diﬀ erent aromatase inhibitors, as 
indirect comparisons in ﬁ gure 5, and direct randomised 
comparisons,16 show little diﬀ erence between drugs. 
It has been hypothesised that the superiority of aromatase 
inhibitors over tamoxifen is greater after previous 
exposure to tamoxifen,17 and the larger recurrence 
reductions reported in years 5–9 in trials of aromatase 
inhibitor versus no further treatment18–20 after 5 years of 
tamoxifen than in trials of 10 versus 5 years of tamoxifen2,3 
provide some support for this. However, the directly 
randomised ﬁ ndings in comparison B do not show any 
eﬀ ect of the type of endocrine therapy during years 0–1 on 
the eﬃ  cacy of treatment during years 2–4, so the apparent 
heterogeneity of beneﬁ t from indirect comparisons could 
be largely chance.
In comparison E, after an initial 2–3 years of an 
aromatase inhibitor there appeared to be no beneﬁ t 
from continuing an aromatase inhibitor to 5 years 
rather than switching to tamoxifen, but this result was 
based on one trial with few events. Hence, it remains 
uncertain whether, after 2–3 years of an aromatase 
inhibitor, any loss of beneﬁ t occurs from switching to 
tamoxifen—reassuringly for women who do not 
tolerate aromatase inhibitors. Results of ongoing trials 
comparing diﬀ erent durations of aromatase inhibitor 
treatment will determine whether, as with tamoxifen, 
longer is better.2,3,21
The reduction in breast cancer mortality with 
aromatase inhibitor compared with tamoxifen is only 
slight, as expected in an already relatively good-prognosis 
population, but persists during years 0–4 and 5–9, 
signiﬁ cantly reducing 10-year breast cancer mortality. 
Overall 10-year mortality was also signiﬁ cantly reduced, 
even though about half the deaths were not due to breast 
cancer. Non-breast cancer death rates were similar with 
aromatase inhibitor and tamoxifen except that, after 
2–3 years of tamoxifen, there appeared to be fewer such 
deaths with an aromatase inhibitor than with continuing 
tamoxifen. This ﬁ nding was unexpected, not explained 
by any one cause, and not replicated in the other 
comparisons. Though likely to be a chance ﬁ nding, it is 
reassuring for the safety of aromatase inhibitors.
Bone fractures are a concern with aromatase inhibitors, 
though the absolute excess of about 0·5% per year might 
be partly explained by a bone-protective eﬀ ect of 
5 years of tamoxifen vs none: EBCTCG 
previous meta-analysis1 (n=10 645)
5 years of aromatase inhibitor vs 5 years 
of tamoxifen: present meta-analyses* 
(n=34 882)
5 years of aromatase inhibitor vs none: 
estimated eﬀ ects (product of two RRs†)
RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value
Breast cancer recurrence
During years 0–4 0·53 (0·48–0·57) 2p<0·0001 0·70 (0·64–0·77) 2p<0·0001 0·37 (0·33–0·42) 2p<0·0001
During years 5–9 0·68 (0·60–0·78) 2p<0·0001 0·92 (0·83–1·01) 2p=0·082 0·63 (0·53–0·74) 2p<0·0001
Breast cancer mortality
During years 0–4 0·71 (0·62–0·80) 2p<0·0001 0·79 (0·67–0·92) 2p=0·002 0·56 (0·46–0·68) 2p<0·0001
During years 5–9 0·66 (0·58–0·75) 2p=0·0001 0·91 (0·80–1·02) 2p=0·12 0·60 (0·50–0·72) 2p<0·0001
EBCTCG=Early Breast Cancer Trialists’ Collaborative Group. RR=rate ratio. *Estimated from the aggregated data (appendix). †Estimated rate ratio for 5 years of aromatase 
inhibitor vs none (RR3) is obtained by direct multiplication of the rate ratio for 5 years of tamoxifen vs none (RR1) by the rate ratio for 5 years of aromatase inhibitor vs 5 years of 
tamoxifen (RR2) estimated from the aggregated data; 95% conﬁ dence limits for RR3 are exp[(o – e)1/v1 + (o – e)2/v2) – 1·96 √(1/v1 + 1/v2)] and exp[(o – e)1/v1 + (o – e)2/v2) + 1·96 √(1/
v1 + 1/v2)], respectively, where (o – e) and v are the observed minus expected statistics and their variances for the comparisons of 5 years of tamoxifen vs none and 5 years of 
aromatase inhibitor vs 5 years of tamoxifen (estimated from aggregated data from trials contributing to subtotal (a) in ﬁ gure 4).
 Table: Estimation of the eﬀ ect of 5 years of an aromatase inhibitor versus no endocrine treatment
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tamoxifen.22 Practitioners need to be aware of this 
complication as monitoring bone health and using 
bisphosphonates if indicated can reduce risk.23 The lower 
endometrial cancer incidence with aromatase inhibitor 
than tamoxifen of around 0·1% per year partly counter-
balances the increased fracture risk.
With full compliance, the beneﬁ t of aromatase 
inhibitors over tamoxifen would probably have been 
somewhat greater than in our intention-to-treat analyses, 
as in addition to the usual levels of dropout in long-term 
trials, which might aﬀ ect both groups similarly, 
substantial crossover of patients from tamoxifen to an 
aromatase inhibitor occurred in two trials,8,9 following 
reports that switching to an aromatase inhibitor after 
2–3 years of tamoxifen reduces recurrence compared 
with continuing tamoxifen.11 The intention-to-treat 
analyses presented throughout this report take no 
account of dropouts or crossovers, so they underestimate 
the superiority of aromatase inhibitor over tamoxifen for 
breast cancer endpoints. Subsequent publications will 
investigate various analytic approaches (eg, as applied to 
BIG 1-9824) to estimate the aromatase inhibitor eﬀ ect that 
would be seen with full compliance.
Among the postmenopausal women in these trials 
there were no signiﬁ cant diﬀ erences in the RR by age. 
Trials of aromatase inhibitors versus tamoxifen in 
premenopausal women treated with an ovarian 
suppressant25,26 were not included. Although age is not 
an independent correlate of distant recurrence or 
treatment eﬃ  cacy, it is a major determinant of the life 
expectancy gain from avoiding distant recurrence. As 
subgroup analyses pooling data from all trials did not 
identify any patient or tumour characteristic that 
strongly predicted the RR, the key quantitative ﬁ ndings 
likely to be generalisable to future patients27 are the 
proportional risk reductions of around 30% in recurrence 
during the aromatase inhibitor versus tamoxifen 
comparison periods, and the proportional reduction of 
about 15% in the breast cancer mortality rate during the 
ﬁ rst decade.
We can infer from the present results the proportional 
reductions that would be achieved with 5 years of 
aromatase inhibitor compared with no adjuvant 
endocrine therapy (table). Treatment with tamoxifen for 
5 years reduces recurrence by about half during years 
0–4 and one-third during years 5–9, and reduces the 
breast cancer mortality rate by about 30% throughout 
the ﬁ rst decade and beyond.1 Therefore, 5 years of an 
aromatase inhibitor compared with no endocrine 
therapy would reduce breast cancer recurrence by about 
two-thirds during treatment and by about one-third 
during years 5–9, and would reduce the breast cancer 
mortality rate by around 40% throughout the ﬁ rst 
decade, and perhaps beyond. Though these proportional 
reductions in risk are approximately independent of 
nodal status, tumour grade, diameter, PR, and HER2 
status, these prognostic factors substantially aﬀ ect the 
absolute risk with no endocrine treatment, and hence 
substantially aﬀ ect the absolute reduction in that risk 
produced by aromatase inhibitors.
Finally, the trials that involve starting endocrine 
treatment with an aromatase inhibitor rather than with 
tamoxifen collectively show a highly signiﬁ cant 30% 
recurrence reduction during years 0–1. The trials 
comparing 5 years of aromatase inhibitor with a 
switching strategy of 2–3 years of tamoxifen then 
aromatase inhibitor to year 5 provide no indication that 
this recurrence reduction during years 0–1 will later be 
lost, and it is likely that it would eventually translate 
into a slight survival improvement. However, in the 
2014 ASCO guidelines on endocrine treatment of 
postmenopausal women with ER-positive early breast 
cancer, three of the four recommended options start 
with tamoxifen;5 a review seems appropriate.
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